Mr Colangelo joins Promedior after a nearly 15-year pharmaceutical industry career at Eli Lilly and Company and most recently as executive vice president of corporate development and operations at Oscient Pharmaceuticals.
Mr Colangelo holds a BSBA in accounting from the State University of New York at Buffalo and a JD degree from the Duke University School of Law.
Joseph Zakrzewski, chairman of board of directors of Promedior, said: “Nick brings a tremendous amount of corporate development, commercial, and pharmaceutical operations experience to Promedior. He is ideally suited to lead Promedior’s next stage of growth as the company prepares to begin clinical development of its lead product candidate.”